Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$192.0B
4,419M shares
52-week range
$35.12 – $64.16
26% from low
Exchange
NYSE
ADRC
P/S (TTM)
0.6
EV / FCF (TTM)
5.8
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
www.novonordisk.comNo one on the platform currently holds NVO.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 3,397,121 | $124.8M |
| Bridgewater Associatesas of 2025-09-30 | 138,947 | $7.7M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-08-17 | $0.5792 | 2026-08-25 |
| 2026-03-30 | $1.2174 | 2026-04-08 |
| 2025-08-18 | $0.5843 | 2025-08-26 |
| 2025-03-31 | $1.1426 | 2025-04-08 |
| 2024-08-16 | $0.5169 | 2024-08-26 |
| 2024-03-22 | $0.9293 | 2024-04-02 |
| Execution date | Ratio |
|---|---|
| 2023-09-20 | 2-for-1 |
| 2014-01-09 | 5-for-1 |
| 2007-12-17 | 2-for-1 |
No one on the platform has traded NVO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 33.6% | 52.7% | 165.9% | — | — | — |
| Rev. Growth % | 6.4% | 19.5% | ||||
| Profit Margin % | 33.1% | 33.8% | 33.7% | |||
| Free Cash Flow Margin % | 9.4% | 26.7% | 28.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +17.7% on the P/E track.
At today's price, your expected annual return is +21.1% on the P/E track.
At today's price, your expected annual return is +25.4% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $301.9B | -2.0% | $22.36 | $19.90–$23.53 | 1.9× | 6 |
| 2027 | $306.2B | +1.4% | $21.83 | $19.85–$23.30 | 2.0× | 7 |
| 2028 | $325.3B | +6.2% | $23.81 | $21.62–$27.38 | 1.8× | 4 |
| 2029 | $349.0B | +7.3% | $26.78 | $24.32–$30.80 | 1.6× | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $0.82 | $0.96 | +17.1% |
| 2026-05-06 | $0.87 | $1.04 | +19.5% |
| 2026-02-03 | $0.90 | $1.00 | +11.1% |
| 2025-11-05 | $0.77 | $1.02 | +32.5% |
| 2025-08-06 | $0.93 | $0.97 | +4.3% |
| 2025-05-07 | $0.92 | $0.92 | +0.0% |
| 2025-02-05 | $0.88 | $0.91 | +3.4% |
| 2024-11-06 | $0.87 |
| $0.88 |
| +1.4% |
| $181.8B |
| — |
| GSKGSK plc | $50.05 | +4.00% | $100.3B | — |
| MRKMerck & Co., Inc. | $144.84 | +0.63% | $357.7B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$NVO the way this stock moves you would think they were going bankrupt.
View on StockTwits ↗
$NVO PE = 10 than LLY 40 LLY figures, quite expensive P/S 13.61 P/B 32.02 P/C 121.18 P/FCF 59.62 EV/EBITDA 27.11 EV/Sales 14.19
View on StockTwits ↗
Eli Lilly To Present Fresh Data On Foundayo, Retatrutide In Europe – Here’s Why Berenberg Sees A 21% Potential Upside In LLY Stock $LLY $NVO https://stocktwits.com/news/equity/markets/eli-lilly-to-present-fresh-data-on-foundayo-retatrutide-in-europe-here-s-why-berenberg-sees-a-21-potential-upside-in-lly-stock/cZtnOoBRBca
View on StockTwits ↗
$NVO they just trying to shake out weak hands.. IM here for long!
View on StockTwits ↗
H.C. Wainwright y'day reitd $CRBP Buy-$35 after CRBP's topline Ph1b for CRB-913, demonstrated a mean weight loss of 5% @ the 60 mg dose by 12 wks & a tolerability profile w/ minimal Gl & psychiatric events that was consistent w/ incretins $VKTX $NVO LLY GPCR Here's what H.C. Wainwright said in its note to investors: https://x.com/Quantumup1/status/2099827838085959893?s=20
View on StockTwits ↗
Berenberg⬆️ $LLY Buy-$1,400 from Hold-$1,220 and said -- Our 2026 RORI analysis published today (RORI 2026) confirms Eli Lilly's strong track record of delivering best-in class returns on investment. $NVO $VKTX AMGN JNJ MRK PFE ABBV BMY Here's what else Berenberg had to say in its note: https://x.com/Quantumup1/status/2099816013562794361?s=20
View on StockTwits ↗
$MNKD there's anecdotes then there's the reality of the findings of $UTHR Martine and the reality that afrezza has such coughing issues that it is has a black box warning label and terrible weekly scripts. Prandial insulin from $LLY and $NVO has no such Black Box Warning label and has been crushing afizzle since it was approved back in 2014 and dumped by $SNY more than a decade ago. afrezza dpi inhaled prandial insulin scripts for week ending 9/4/26 nrx 346 refills 492 ...
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.